CLPT trades 8.5% above Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLPT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, ClearPoint Neuro, Inc. (CLPT) has a Wall Street consensus price target of $16.00, based on estimates from 3 covering analysts. With the stock currently trading at $17.48, this represents a potential downside of -8.5%. The company has a market capitalization of $524M.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLPT trades at a trailing P/E of -19.4x. Analysts expect EPS to grow -13.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
ANGOAngioDynamics, Inc. | $540M | $13.07 | $16.50 | +26.2% | Hold | — | 11 |
ATECAlphatec Holdings, Inc. | $1.4B | $9.38 | $18.00 | +91.9% | Buy | 29.3x | 18 |
GEGE Aerospace | $383.4B | $366.98 | $393.00 | +7.1% | Buy | 48.6x | 34 |
GEHCGE HealthCare Technologies Inc. | $29.5B | $64.89 | $81.00 | +24.8% | Buy | 13.3x | 18 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
Quick answers to the most common questions about buying CLPT stock.
Wall Street's consensus price target for CLPT is $16, -8.5% from its current price of $17.48. The below-market target from 3 analysts suggests limited near-term appreciation.
CLPT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies -8.5% downside from current levels.
CLPT's current price is $17.48 with a consensus target of $16 (-8.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $16 for CLPT, while the most conservative target is $16. The consensus of $16 represents the median expectation. These targets typically reflect 12-month expectations.
CLPT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLPT stock forecast based on 3 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy".
Analysts are cautious on CLPT, with 0 Sell ratings and a price target of $16 (-8.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLPT analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.